Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities research analysts at Leerink Swann boosted their FY2018 earnings estimates for Myriad Genetics in a research note issued to investors on Wednesday. Leerink Swann analyst P. Souda now expects that the company will post earnings of $1.14 per share for the year, up from their prior forecast of $1.04. Leerink Swann currently has a “Market Perform” rating and a $35.00 target price on the stock. Leerink Swann also issued estimates for Myriad Genetics’ Q1 2019 earnings at $0.29 EPS, Q2 2019 earnings at $0.29 EPS, Q3 2019 earnings at $0.30 EPS, Q4 2019 earnings at $0.33 EPS and FY2019 earnings at $1.20 EPS.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.24 by $0.07. The firm had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. Myriad Genetics had a return on equity of 9.94% and a net margin of 16.67%. The company’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.26 EPS.
Shares of Myriad Genetics (NASDAQ MYGN) traded down $0.13 during trading on Thursday, hitting $33.70. The stock had a trading volume of 356,064 shares, compared to its average volume of 761,622. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The company has a market cap of $2,479.51, a price-to-earnings ratio of 18.29, a PEG ratio of 2.26 and a beta of 0.32. Myriad Genetics has a 12-month low of $15.71 and a 12-month high of $41.57.
In other Myriad Genetics news, VP Richard M. Marsh sold 13,759 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $36.25, for a total value of $498,763.75. Following the completion of the transaction, the vice president now owns 136,385 shares in the company, valued at $4,943,956.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Richard M. Marsh sold 37,654 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $40.25, for a total transaction of $1,515,573.50. Following the completion of the transaction, the vice president now owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The disclosure for this sale can be found here. Insiders sold a total of 71,064 shares of company stock worth $2,679,097 over the last three months. Corporate insiders own 6.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in MYGN. Wells Fargo & Company MN lifted its position in Myriad Genetics by 98.2% in the third quarter. Wells Fargo & Company MN now owns 844,339 shares of the company’s stock valued at $30,548,000 after acquiring an additional 418,335 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Myriad Genetics by 18.4% in the fourth quarter. Acadian Asset Management LLC now owns 2,205,297 shares of the company’s stock valued at $75,743,000 after buying an additional 343,196 shares during the last quarter. Northern Trust Corp increased its stake in shares of Myriad Genetics by 31.1% during the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock worth $33,400,000 after acquiring an additional 306,276 shares during the period. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Myriad Genetics during the third quarter worth about $9,083,000. Finally, Robeco Institutional Asset Management B.V. acquired a new position in shares of Myriad Genetics during the fourth quarter worth about $5,979,000.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/08/myriad-genetics-inc-forecasted-to-earn-fy2018-earnings-of-1-14-per-share-mygn.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.